Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
about
Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressorVHL type 2B mutations retain VBC complex form and functionFIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activityA yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor proteinIdentification of novel VHL target genes and relationship to hypoxic response pathwaysThe von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHLSomatic HIF2A gain-of-function mutations in paraganglioma with polycythemiavon Hippel-Lindau disease: a clinical and scientific reviewState of the science: an update on renal cell carcinomaThe VHL tumor suppressor: master regulator of HIFpVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growthA common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylationA HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomasGene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paragangliomaInactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.The role of PHD2 mutations in the pathogenesis of erythrocytosis.Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients.Meet me halfway: when genomics meets structural bioinformatics.Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.Paragangliomas/Pheochromocytomas: clinically oriented genetic testingGenetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesisGenotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotypeMutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibilityMolecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in miceProteomic dissection of the von Hippel-Lindau (VHL) interactome.VHL, the story of a tumour suppressor gene.Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinomaThe von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.P.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization.MRI of the tumor microenvironment.Akt-induced phosphorylation of N-CoR at serine 1450 contributes to its misfolded conformational dependent loss (MCDL) in acute myeloid leukemia of the M5 subtype.
P2860
Q21135547-F5F64E5B-8228-4B54-8EFE-9AD2C6655649Q21144205-3C2F7673-55B9-4EFF-8CBC-BFECFDF5D4EFQ24291819-FD8C4BD5-B27D-459B-B06B-05FFB9C0D458Q24299850-53F8DA0C-9FCF-4979-BE5F-0F6CA90AFACFQ24299968-A484EBFA-22F9-42A9-A9DA-91CD68A425CDQ24304165-A86D32E2-EE01-4348-A1EA-13C202A31AA3Q24321579-97DFBC72-F630-4E4F-9AD4-0126F5049C91Q24607557-DFC8942F-DD30-4466-B1A2-47DE07FCEAACQ24622030-6047D405-EE5B-4C94-A038-4B09BE7E1F4CQ24630685-ACA50890-EA58-49E3-9C01-7C958F6EE6A5Q24634592-547761B8-CD2D-4252-B52E-2364D7891A2EQ24684757-D388A287-46DD-4E71-BA97-7F24DE520F03Q24800550-4AD546A3-95A1-4BB3-A1A5-B3DA97D6B21AQ24802803-3F67A67E-3142-4BB0-A323-73ADB454786FQ24811594-FAF5F3AC-D4E0-458C-9885-ACD6A14181B8Q28366764-DC7A1FB5-3659-4E9C-B689-4DFBC8B2B4AFQ28590550-53403DF8-474E-4AC5-9DEF-EA7D53C3C5ACQ28598099-32FB80A7-9E26-4FFC-A46C-47A5271AD339Q30252701-928873D4-58B7-4119-8FAB-333D019B9855Q30400158-F8EFD749-30E6-47F2-92C5-3E3D74344241Q33425920-86D852E8-3FA9-4C90-9EFB-273E5B224C44Q33481999-7424631A-9AA1-43B8-9DC9-43E46E2961A5Q33586709-F7CB27E9-6E54-4C82-A015-15BDF74009C7Q33679204-48092C2A-D2BE-4AB4-8CEA-32CDBCC07AD0Q33719533-2CF68B64-1BD5-43B4-A962-6A754BB7885DQ33905244-588F0FA0-8814-44C3-9E3F-59643B9F133EQ33909500-E75886B5-1EEB-4504-B563-A50E7535BD10Q34045653-AA6C17D6-C490-48F9-890F-29153CDC74DCQ34135425-AE46FC47-8500-4F16-8530-B8FDB442CE42Q34144574-37FFED72-3D43-4CF1-9D65-5E5E4D3A5F30Q34149009-D9716C0C-EDA9-4A68-952F-778545D6EB22Q34218966-64BA6082-3B14-446B-A55C-CC05E7A0AACAQ34455226-566A689C-CB2E-4769-957D-FDB3CC7B5F3DQ34530199-2476E952-D4F7-4B1C-8163-C43C2EACB469Q34536583-A6B45842-B577-4AFC-ACFC-87635AF2856CQ34539288-81F24CFD-AD51-40E4-B90E-A8DBF995D1E0Q34569380-5795BCD3-A813-425A-B858-20150F45BC7FQ34692517-10580E9A-4CA7-41D6-9488-C37A66E40ECAQ34918656-92409AE5-8F01-4824-8F3F-95996A00E382Q34936302-D553ED99-EBB3-48D7-AE9B-FDDD6F34BE4E
P2860
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@ast
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@en
type
label
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@ast
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@en
prefLabel
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@ast
Contrasting effects on HIF-1al ...... in von Hippel-Lindau disease.
@en
P2093
P50
P356
P1476
Contrasting effects on HIF-1al ...... s in von Hippel-Lindau disease
@en
P2093
A C Smallwood
E R Woodward
P H Maxwell
S C Clifford
P304
P356
10.1093/HMG/10.10.1029
P577
2001-05-01T00:00:00Z